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Abstract
Background: There is a long-established association between rheumatoid arthritis and HLA-
DRb1. The shared epitope (SE) allele is an indicator of the presence of any of the HLA-DRb1 alleles
associated with RA. Other autoantibodies are also associated with RA, specifically rheumatoid
factor IgM (RFUW) and anti-cyclic citrullinated peptide (anti-CCP).
Methods: Using the Genetic Analysis Workshop 16 North American Rheumatoid Arthritis
Consortium genome-wide association data, we sought to find non-HLA-DRb1 genetic associations
by stratifying across SE status, and using the continuous biomarker phenotypes of RFUW and anti-
CCP. To evaluate the binary RA phenotype, we applied the recently developed FP test and
compared it to logistic regression or a genotype count-based test. We adjusted for multiple testing
using the Bonferroni correction, the Q value approach, or permutation-based p-values. A case-only
analysis of the biomarkers RFUW and anti-CCP used linear regression and ANOVAs.
Results: The initial genome-wide association analysis using all cases and controls provides
substantial evidence of an association on chromosomes 9 and 2 within the immune system-related
gene UBXD2. In SE-positive subjects, many single-nucleotide polymorphisms were significant,
including some on chromosome 6. Due to very few SE negative cases, we had limited power to
detect associations in SE negative subjects. We were also unable to find genetic associations with
either RFUW or anti-CCP.
Conclusion: Our analyses have confirmed previous findings for genes PTPN22 and C5.W ea l s o
identified a novel candidate gene on chromosome 2, UBXD2. Results suggest FP test may be more
powerful than the genotype count-based test.
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Geneticassociationsbetweenrheumatoidarthritis(RA)and
HLAlocihavebeenknownforsome30years[1]butonlyin
recent times, with the availability of dense genetic maps,
haveassociationswithothergenomicareasbeendiscovered.
An affected-sibpair analysis demonstrated significant link-
age of RA with single-nucleotide polymorphisms (SNPs)
at chromosomes 2q33 and 11p12 with additional, non-
significant, linkage to SNPs on chromosomes 4, 7, 12, 16,
and 18 [2]. Genome-wide association studies have con-
firmed and refined associations with HLA variants [3-5],
specifically with HLA-DRb1. The high risk alleles for HLA-
DRb1, commonly referred to as the shared epitope (SE),
were found to be highly associated with RA [6,7]. Thus,
individuals can be characterized as SE positive (at least one
high risk allele) or SE negative (no high risk alleles). Lee
et al. [8] have recently shown that there are associations
within the major histocompatibility complex (MHC) that
are independent of HLA-DRb1. Autoantibodies, such as
rheumatoid factor IgM (RFUW) and anti-cyclic citrullinated
peptide (anti-CCP) have been shown to co-occur with RA
[9-11]. Thus, genetic predictors of these two biomarkers
may also be of interest.
Using unrelated cases and controls from the North
American Rheumatoid Arthritis Consortium (NARAC)
[12] provided by the Genetic Analysis Workshops 16 and
previously analyzed by Plenge et al. [4], we sought to
find non-HLA-DRb1 genetic associations separately in SE
positive and SE negative individuals. The literature does
not contain any analysis of genome-wide association
adjusted for SE status; thus, our primary objective was to
stratify the genetic analyses by SE status. Our aims are to
identify genomic regions in SE negative individuals that
may act independently of the SE in RA development, to
evaluate any potential effect modification or epistasis
with HLA-DRb1 in SE positive individuals, and to
identify new genomic regions associated with the
continuous phenotypes of RFUW and anti-CCP. We
also sought to implement the recently proposed FP test
[13] and compare it to other methods of analysis.
Methods
Quality control
As previously noted, heterogeneity in this dataset is
largely due to SNPs with incomplete genotyping [4].
Thus, we focused on the subset of SNPs with call rates
exceeding 95.5%. Markers with only one genotype
observed were excluded as well as those with a minor
allele frequency (MAF) less than 5%. Further, SNPs with
the c
2 for Hardy-Weinberg disequilibrium greater than
50 were also removed from consideration. Individuals
with more than 20% of SNPs missing were excluded.
Only autosomal SNPs were analyzed in this study.
Statistical analysis
As an initial pass through the data, a genome-wide
association analysis was performed using the FP test and a
genotype-based c
2 test of association for all non-chromo-
some6SNPs.TheseSNPswereignoredatfirstbecauseofthe
potential for disequilibrium with the HLA-DRb1. These
analyses considered all cases and controls, that is, the
number of SE alleles was not accounted for in any way. The
FP test evaluates differences in allele frequencies and
inbreeding coefficients between cases and controls. Both
statistics were implemented using the sumstat program [14]
which computes permutation-based p-values such that
further adjustment for multiple testing is unnecessary. For
all analyses, 5000 permutations were used.
For the genome-wide association analyses of RA adjusting
for SE status, we performed multiple methods of analyses
separately in those who are SE positive and those who are
SE negative. Three different analytic methods were applied
to each SNP. First, logistic regressions were implemented in
PLINK [15] with sex as an additional covariate. For these
results, multiple comparisons were adjusted for using the
Bonferroni correction as well as the Q value approach [16],
which controls the false discovery rate (FDR). Due to the
large number of statistically significant SNPs in this
analysis, all subsequent analyses do not consider any
SNPs on chromosome 6. As in the initial analyses, both the
c
2 test of genotype-based association and the FP test were
implemented in sumstat using 5000 permutations.
Genetic analysis of the two biomarkers RFUW and anti-
CCP were conducted in a similar fashion, but only
considering the 868 cases. Since these outcome variables
are continuous, linear regression with sex as an additional
covariate was implemented using PLINK. The quantile rank
transformation was applied to both outcomes to satisfy
distribution assumptions. Multiple testing was adjusted for
using the Bonferroni and Q value approaches. ANOVAs
were used to analyze the biomarkers separately and jointly
using sumstat and its permutation-based p-values. Due to
the normality assumptions of this approach, anti-CCP and
RFUW levels were transformed using the normal quantile
transformation. For each SNP, three tests were considered:
i) ANOVA considering only anti-CCP, ii) ANOVA con-
sidering RFUW alone, and iii) the maximum ANOVA
statistic for anti-CCP and RFUW. The permutations
implemented by sumstat allow for control of the type I
error rate for the maximum statistic and multiple testing
simultaneously.
Results
Quality control
Initially, 531,689 autosomal SNPs were available for
analysis. Due to only one genotype being observed,
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deviations from Hardy-Weinberg equilibrium, 22 SNPs
were also removed. Further, another 38,829 SNPs did
not pass quality control because their MAF was less than
5%. After also removing SNPs with call rates less than
95.5%, we were able to consider 481,486 autosomal
SNPs. For the genotype-based analyses and FP tests,
chromosome 6 SNPs were excluded, leaving 338,671 for
this set of analyses. Because the lowest call rate was over
97%, we considered all 2062 subjects.
Initial genome-wide association analysis
Twelve non-chromosome 6 SNPs were statistically
significant in the initial pass through the data using the
FP or c
2 test of association with genotype counts. Table 1
describes these “best” non-chromosome 6 SNPs and the
permutation-based p-values for both tests. There are six
SNPs on chromosome 9 that are statistically significant
at the 0.05 level, all within 65 kb of each other. The
remaining significant SNPs are located on chromosomes
1, 2, 8, and 10.
Adjusting for SE status
Of the 868 cases, 810 were SE positive; and of the 1194
controls, only 541 were SE positive. Figure 1A gives the
results of the logistic regression analyses of all autosomal
SNPs in the 1351 individuals who are SE positive. Using
the Bonferroni correction, there were statistically signifi-
cant SNPs on virtually every autosome. The most highly
significant SNPs are located on chromosome 6 in the HLA
region, with several p- v a l u e sl e s st h a n1 0
-25.F i g u r e1 Bp l o t s
the results of the logistic regression analyses of all
autosomal SNPs in the SE negative participants. None of
the over 480,000 SNPs were statistically significant in the
SE negative individuals after adjustment for multiple
comparisons with the Bonferroni or Q value corrections.
When the chromosome 6 SNPs are excluded from analysis
and the FP test is implemented, only one SNP was
statistically significant for SE positive subjects: rs2900180
(p = 0.0196) on chromosome 9. In SE negative individuals,
no SNPs were statistically significant (all p > 0.35) using the
FP test.
Analysis of anti-CCP and rheumatoid factor IgM
The quantitative trait analyses of anti-CCP and RFUW
were performed using cases only because this informa-
tion was only available on the 868 subjects with RA. Not
a single SNP was significant using any of the methods
a b o v e .D u et ot h es m a l ls a m p l es i z ea n dt h ef a c tt h a ta l l
subjects had RA, we may have lacked power to detect any
genetic association with levels of anti-CCP or RFUW.
Discussion
When considering all cases and controls regardless of SE
status, 12 SNPs were statistically significant and spread
across chromosomes 1, 2, 8, 9, and 10. The most
significant SNP, rs2476601, is located on chromosome 1
less than 1 Mb from the PTPN22 gene, which has been
shown to be associated with RA [14,17]. Six SNPs on
chromosome 9 were also significant with the FP test, and
they are all located in the same region: 120.72 to 120.79
Mb. These results may be due to high linkage disequili-
brium (LD); in fact, three pairs of these SNPs have r
2
greater than 0.8. This region of chromosome 9, located
near the immunity-related complement compound 5
(C5) gene, has been previously identified as associated
with RA [4,18]. Three new associations are suggested by
our analyses. On chromosome 8, three SNPs were
statistically significant and are all located within 10 kb
of each other. Yet another SNP was significant on
chromosome 10 using the FP test, but was not significant
using the genotype-based c
2 test. Interestingly, we found
evidence of an association on chromosome 2 at
rs1446585, which is 35 Mb from a signal reported by
Plenge et al. [4]. Our SNP is located within the UBXD2
gene, which has been shown to be differentially
expressed in the spleen and plays a role in the immune
Table 1: Analysis of non-chromosome 6 SNPs using all subjects
SNP ID Chromosome Location (bp) FP (p-value) Genotype-based c
2 (p-value)
rs2476601 1 114089610 <0.0001 <0.0001
rs2900180
a 9 120785936 0.003 0.014
rs3761847 9 120769793 0.006 0.031
rs881375 9 120732452 0.011 0.046
rs2671692 10 49767825 0.011 0.057
rs1953126 9 120720054 0.012 0.053
rs10760130 9 120781544 0.013 0.064
rs4921720 8 20397678 0.024 0.123
rs11204117 8 20396191 0.026 0.131
rs10106243 8 20388180 0.031 0.153
rs1446585 2 136241211 0.034 0.163
rs10985073 9 120723409 0.035 0.165
aAlso significant using FP test only on individuals with shared epitopes.
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Manhattan plots from the logistic regression analysis of RA stratifying by SE status.A ,R e s u l t sf r o mt h er e g r e s s i o n
analyses in SE positive subjects adjusted for sex using all autosomal SNPs, including chromosome 6. B, Results from the
regression analyses in SE negative subjects adjusted for sex using all autosomal SNPs, including chromosome 6.
BMC Proceedings 2009, 3(Suppl 7):S12 http://www.biomedcentral.com/1753-6561/3/S7/S12
P a g e4o f6
(page number not for citation purposes)s y s t e m[ 1 9 ] .T h i si sp a r t i c u l a r l yo fi n t e r e s tb e c a u s eR Ai s
an autoimmune disease.
One goal of our genome-wide association analysis was to
stratify bySE status,which has not beendone previouslyfor
a genome-wide association study. Using the FP test on SE
positive subjects, only one SNP was statistically significant,
namely, rs2900180, which is located within approximately
2M bo fC5. More SNPs were significant in this region near
C5 when all subjects were considered, but this difference
doesnot implyepistasisbetweenC5 andHLA-DRb1.It may
only be due to the decrease in sample size. When restricting
our analysis to SE negative individuals, none of the three
tests yielded evidence of another gene associated with the
development of RA. The increase in risk associated with the
shared epitope allele is so great that very few of the cases
were SE negative. With only 58 cases available for these
analyses, it is not surprising no SNPs were significant.
Although one of our main objectives was to identify
genomic regions that may act independently on develop-
ment and progression of RA, we were unable to do so with
adequate power.
Ouranalysesofthebiomarkersanti-CCPandRFUWyielded
no significant results. Information on these continuous
phenotypes was only available for the 868 cases, so the
controlswerenotconsideredatall.SinceallsubjectshadRA,
it may be that there is no genetic association with either
biomarkeroncediseasehasdevelopedorprogressed.RFUW
is a measure of disease activity, so the lack of observed
association may be due to the study design such that cases
are fairly homogeneous in terms of disease severity.
Our final goal was to compare the implementation of
the FP test with the other methods employed here. The
significance level approach based on the FP test found
far fewer SNPs to be statistically significant than the
FDR approach (i.e., Q value) based on logistic regression
analysis. This may show superiority of the concept of
controlling the FDR over the significance level approach,
and/or this difference may be due to inclusion in the
logistic regression analysis of predictor variables, which
were not considered in the FP analyses. Because
permutation-based p-values were used for the FP and
genotype-based c
2 test in Table 1, the fact that the FP has
smaller p-values than the c
2 test for each SNP indicates
the former may be more powerful.
Conclusion
This study demonstrates that there may be several genes
that co-function with HLA-DRb1 in the development
and severity of RA, most likely on chromosome 9, such
as C5, and other genes within the MHC region on
chromosome 6. We have also identified another region
on chromosome 2 near the UBXD2 gene as a candidate
for follow-up study. In addition, we have shown that in
order to identify new genomic regions that cause RA in
SE negative individuals, an alternative study design must
be implemented.
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